Cargando…
Sebelipase alfa for lysosomal acid lipase deficiency: 5‐year treatment experience from a phase 2 open‐label extension study
BACKGROUND AND AIMS: Lysosomal acid lipase deficiency is characterized by hepatomegaly and dyslipidaemia, which can lead to cirrhosis and premature atherosclerosis. Sebelipase alfa is an approved recombinant human lysosomal acid lipase. In an open‐label extension study of adults with lysosomal acid...
Autores principales: | Malinová, Vĕra, Balwani, Manisha, Sharma, Reena, Arnoux, Jean‐Baptiste, Kane, John, Whitley, Chester B., Marulkar, Sachin, Abel, Florian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540377/ https://www.ncbi.nlm.nih.gov/pubmed/32657505 http://dx.doi.org/10.1111/liv.14603 |
Ejemplares similares
-
Survival in infants treated with sebelipase Alfa for lysosomal acid lipase deficiency: an open-label, multicenter, dose-escalation study
por: Jones, Simon A., et al.
Publicado: (2017) -
Novel treatment options for lysosomal acid lipase deficiency: critical appraisal of sebelipase alfa
por: Su, Kim, et al.
Publicado: (2016) -
Long-term survival with sebelipase alfa enzyme replacement therapy in infants with rapidly progressive lysosomal acid lipase deficiency: final results from 2 open-label studies
por: Vijay, Suresh, et al.
Publicado: (2021) -
Correction to: Long-term survival with sebelipase alfa enzyme replacement therapy in infants with rapidly progressive lysosomal acid lipase deficiency: final results from 2 open-label studies
por: Vijay, Suresh, et al.
Publicado: (2021) -
Case series of sebelipase alfa hypersensitivity reactions and successful sebelipase alfa rapid desensitization
por: Huffaker, Michelle F., et al.
Publicado: (2019)